Raffaele Califano, MD / Nicolas Girard, MD, PhD / Antonio Passaro, MD, PhD - Reshaping the Management of Metastatic NSCLC: Tackling HER2 Overexpression to Elevate Outcomes

Please visit answersincme.com/860/98320325-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the evolving role of HER2-targeted antibody–drug conjugates (ADCs) and how to integrate them into clinical practice. Upon completion of this activity, participants should be better able to: Recognize the role of biomarker testing for the management of HER2-overexpressing NSCLC; Evaluate the clinical significance of new and emerging HER2-targeting ADCs for HER2-overexpressing NSCLC; and Apply strategies to optimize the use of HER2 targeting ADCs in patients with NSCLC.

Please visit answersincme.com/860/95719487-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in vaccine-preventable diseases discuss the most up-to-date evidence-based recommendations for flu vaccination, as well as strategies to enhance uptake across all age groups. Upon completion of this activity, participants should be better able to: Discuss the therapeutic rationale for seasonal influenza vaccination across all age groups; Describe the clinical profiles of recommended influenza vaccines; and Outline practical strategies to enhance influenza vaccination uptake across all age groups.

Please visit answersincme.com/XWJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, a retina expert discusses the role of long-acting anti–vascular endothelial growth factor (VEGF) therapy in neovascular age-related macular degeneration (nAMD). Upon completion of this activity, participants should be better able to: Recognize the rationale for long-acting anti-VEGF therapy in nAMD; Select the optimal long-acting anti-VEGF therapy for individual patients with nAMD; and Integrate practical strategies to enhance the clinical implementation of long-acting anti-VEGF therapy in patients with nAMD.

Please visit answersincme.com/QWE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cardiology discusses the evolving role of mineralocorticoid receptor antagonists (MRAs) to treat patients with heart failure. Upon completion of this activity, participants should be better able to: Identify the evolving role of mineralocorticoid receptor antagonists (MRAs) to treat patients with heart failure; Evaluate clinical implications of the latest data on nonsteroidal MRAs for the treatment of heart failure and mildly reduced ejection fraction (HFmrEF) or heart failure and preserved ejection fraction (HFpEF), in the context of current standard-of-care; and Describe strategies to incorporate nonsteroidal MRAs into the treatment plans of patients with HFmrEF or HFpEF.

Please visit answersincme.com/NPK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in multiple myeloma (MM) answers common questions about incorporating novel cereblon E3 ligase modulators (CELMoDs) in early-relapse therapy for patients with MM. Upon completion of this activity, participants should be better able to: Identify the rationale for incorporating novel CELMoDs in early-relapse therapy in patients with MM; Discuss the clinical impact of the latest data for emerging novel CELMoDs in the early-relapse setting for patients with MM; and Describe potential considerations for integrating novel CELMoDs in the treatment landscape of MM as they become available.

Please visit answersincme.com/JCY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in dermatology discuss the current and potential clinical impact of TYK2 inhibitors. Upon completion of this activity, participants should be better able to: Contrast the clinical implications of selective TYK2 inhibition versus pan-JAK inhibition in the treatment of moderate-to-severe plaque psoriasis; Interpret the clinical evidence for next-generation TYK2 inhibitors in patients with moderate-to-severe plaque psoriasis; and Integrate TYK2 inhibitors into clinical practice as they become available for patients with moderate-to-severe plaque psoriasis.

Please visit answersincme.com/HSJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in urothelial cancer discusses biomarker testing for patients with locally advanced/metastatic urothelial cancer. Upon completion of this activity, participants should be better able to: Recognize the impact of biomarker testing on patient outcomes with novel approved therapies in locally advanced/metastatic UC (LA/mUC); Identify optimal strategies for implementing biomarker testing in clinical practice; and Outline patient-centered strategies to optimize outcomes following the identification of actionable biomarkers.

Please visit answersincme.com/ZXA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in interstitial lung disease (ILD) discuss the latest information, including post-congress insights, on advancing patient-centered ILD care with antifibrotics, treatment innovations, and multidisciplinary approaches. Upon completion of this activity, participants should be better able to: Assess recommended antifibrotic treatment for patients with ILDs; Review the rationale for novel therapy for fibrosing ILDs; and Outline multidisciplinary, patient-centered strategies to enhance care for individuals with ILDs.

Please visit answersincme.com/860/97851223-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in lung cancer discuss the practical application of immunotherapy-based regimens for the treatment of extensive-stage small-cell lung cancer (ES-SCLC). Upon completion of this activity, participants should be better able to: Review the clinical impact of immunotherapy-based regimens for the management of small-cell lung cancer (SCLC); and Outline personalized treatment strategies to address key complexities affecting the optimal, real-world management of patients with SCLC.

Please visit answersincme.com/XFS860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in esophageal disease addresses common queries related to the diagnosis and management of eosinophilic esophagitis (EoE). Upon completion of this activity, participants should be better able to: Identify diagnostic criteria and practical strategies to facilitate the timely diagnosis of EoE; Review the clinical impact of pharmacotherapies in patients with EoE; and Discuss personalized strategies to optimize patient outcomes with pharmacotherapies in EoE.